Skip to content

Amniotic Membrane Wrapping and Tenolysis Versus Tenolysis Alone for Treatment of Tendon Adhesions of the Hand/Wrist

A Prospective Randomized Trial Comparing Tendon Wrapping With Amniotic Membrane and Tenolysis Versus Tenolysis Alone for Treatment of Tendon Adhesions of the Hand and Wrist

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03013582
Enrollment
40
Registered
2017-01-06
Start date
2017-01-31
Completion date
Unknown
Last updated
2017-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adhesions Nos Postoperative, Fibrosis, Scar, Tendinopathy

Brief summary

Tendon adhesions of the hand remain a ubiquitous problem facing hand surgeons and hand therapists alike. Despite their commonality, no consensus exists as to the best means of preventing adhesions, or the most ideal methods to treat them once they have occurred. The purpose of this study is to compare patient outcomes after standard operative tenolysis performed for adhesions of the hand to outcomes after tenolysis with the use of allograft human amniotic membrane.

Detailed description

Patients who are scheduled to undergo operative tenolysis of the flexor and/or extensor tendons of the hand will be recruited. Our target enrollment is 40 patients (20 control plus 20 experimental), based on the power analysis detailed in the next paragraph. Enrolled patients will be randomized to either standard operative tenolysis, or tenolysis with placement of AlloWrap. Randomization will be performed by computerized random number generator. All surgeries will be performed by one senior fellowship-trained hand surgeon. Baseline measurements of total active motion (TAM), passive range of motion (PROM), and survey scores of the Quick Disabilities of the Arm, Shoulder and Hand (QuickDASH) and Patient Rated Wrist Evaluation (PRWE) will be recorded pre-operatively. In addition, patients' pain level will be assessed using the visual analog scale (VAS) both at rest, and during the examination. These same values will be re-evaluated at post-operative follow-up visits at 2 weeks, 1 month, 3 months and 6 months. PROM will also be evaluated intra-operatively by the surgeon, and documented.

Interventions

BIOLOGICALAmnion Tendon Wrapping

Tendon is wrapped with the allograft

PROCEDURESurgical Tenolysis

Surgical release of peritendinous scarred tissue

Sponsors

Thomas Jefferson University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All adult patients deemed candidates for operative tenolysis of the hand or wrist * Age ≥18

Exclusion criteria

* Patients younger than 18 years at the time of surgery; * Any patient who would not be able or willing to comply with the protocol or perform assessments; * Patients with medical conditions that may preclude placement of human biological membrane; * Patients who have previously undergone tenolysis on the operative hand; * Patients that will have multiple surgeries that are deemed as possible confounders, particularly those requiring an additional incision; * Is physically or mentally compromised (i.e. being currently treated for a psychiatric disorder, senile dementia, Alzheimer's disease) in a manner that would compromise his or her ability to participate in the clinical study; * Is a prisoner; * Is a transient.

Design outcomes

Primary

MeasureTime frame
Total Active Motion (TAM)6 months
Passive Range of Motion (PROM)6 months

Secondary

MeasureTime frameDescription
Patient-Rated Wrist Evaluation (PRWE)6 monthsValidated Outcome score/questionnaire specific to wrist function
Quick Disabilities of the Arm, Shoulder and Hand (QuickDASH)6 monthsValidated Outcome score/questionnaire generalized to upper extremity conditions
Complications2 weeks, One month, 3 months, 6 months

Contacts

Primary ContactMichael P Gaspar, MD
michaelpgaspar@gmail.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026